C. Sizemore

发表

Extracellular expression of native human anti-lysozyme fragments in Staphylococcus carnosus.

W. Hillen, D. Schnappinger, W. Geißdörfer, 1995, FEMS microbiology letters.

Developing vaccines to prevent sustained infection with Mycobacterium tuberculosis: Conference proceedings: National Institute of Allergy and Infectious Diseases, Rockville, Maryland USA, November 7, 2014.

Richard G. White, E. Nardell, S. Self, 2015, Vaccine.

Developing aerosol vaccines for Mycobacterium tuberculosis: Workshop proceedings: National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, April 9, 2014.

W. Hanekom, A. Hickey, R. Seder, 2015, Vaccine.

Combinatorial chemistry and natural products. Teicoplanin aglycone as a molecular scaffold for solid phase synthesis of combinatorial libraries

P. Seneci, C. Sizemore, K. Islam, 1996 .

Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research

J. Sacchettini, S. Holland, R. Coler, 2019, American journal of respiratory and critical care medicine.

The role of biomedical research in global tuberculosis control: gaps and challenges

C. Sizemore, Amanda C Schleif, J. Bernstein, 2012, Emerging Microbes & Infections.

The Changing Face of Biomedical Research in Tuberculosis

C. Sizemore, C. Heilman, 2008 .

Glutamyl-γ-boronate inhibitors of bacterial Glu-tRNAGln amidotransferase

D. J. Nelson, R. Copeland, K. Horiuchi, 2001 .

Editorial: NTM—The New Uber-Bugs

T. Dick, V. Dartois, C. Sizemore, 2019, Front. Microbiol..

Parallel synthesis of potent, pyrazole-based inhibitors of Helicobacter pylori dihydroorotate dehydrogenase.

J. Marcinkeviciene, G. Trainor, F. Hobbs, 2002, Journal of medicinal chemistry.

Helicobacter pylori-selective Antibacterials Based on Inhibition of Pyrimidine Biosynthesis*

J. Marcinkeviciene, G. Trainor, F. Hobbs, 2000, The Journal of Biological Chemistry.

Safety and Efficacy Assessment of Two New Leprosy Skin Test Antigens: Randomized Double Blind Clinical Study

P. Brennan, D. She, B. Sapkota, 2014, PLoS neglected tropical diseases.

An array of target-specific screening strains for antibacterial discovery

Jonathan A. Mills, D. Pompliano, C. Sizemore, 2002, Nature Biotechnology.

Plan to combat extensively drug-resistant tuberculosis; recommendations of the Federal Tuberculosis Task Force

K. Castro, P. Lobue, C. Sizemore, 2009 .

Using fusions with luxAB from Vibrio harveyi MAV to quantify induction and catabolite repression of the xyl operon in Staphylococcus carnosus TM300.

W. Hillen, W. Geißdörfer, C. Sizemore, 1993, FEMS microbiology letters.

Regulation of Staphylococcus xylosus xylose utilization genes at the molecular level

W. Hillen, F. Götz, C. Sizemore, 1992, Journal of bacteriology.

Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions

S. Swaminathan, F. Cobelens, G. Kaplan, 2016, PLoS medicine.

Transforming biomedical research to develop effective TB vaccines: the next ten years.

A. Fauci, C. Sizemore, 2012, Tuberculosis.

Organization, promoter analysis and transcriptional regulation of the Staphylococcus xylosus xylose utilization operon

W. Hillen, F. Götz, C. Sizemore, 1991, Molecular and General Genetics MGG.

Effects of Metronidazole, Tetracycline, and Bismuth-Metronidazole-Tetracycline Triple Therapy in the Helicobacter pylori SS1 Mouse Model after 1 Day of Dosing: Development of an H. pylori Lead Selection Model

A. Slee, C. Sizemore, D. A. Stevenson, 2002, Antimicrobial Agents and Chemotherapy.

Quantitative analysis of Tn10 Tet repressor binding to a complete set of tet operator mutants.

W. Hillen, A. Wissmann, W Hillen, 1990, Nucleic acids research.

Tuberculosis vaccine development: research, regulatory and clinical strategies

M. Brennan, S. Morris, C. Sizemore, 2004, Expert opinion on biological therapy.

Viewpoint: Challenges and Opportunities in Tuberculosis Research

R. Hafner, P. Kim, C. Sizemore, 2012, The Journal of infectious diseases.

Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research.

C. Lienhardt, C. Sizemore, Alison M. Kraigsley, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Advancing the development of diagnostic tests and biomarkers for tuberculosis.

B. Plikaytis, L. Sacks, Y. Yasinskaya, 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Clinical research and development of tuberculosis diagnostics: moving from silos to synergy.

Wendy S Stevens, Jane Diefenbach, David Alland, 2012, The Journal of infectious diseases.

Clinical Research and Development ofTuberculosis Diagnostics: Moving From Silos toSynergy

M. Perkins, G. Ireton, C. Hamilton, 2012 .

Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development

K. Romero, E. Nuermberger, D. Hanna, 2016, Antimicrobial Agents and Chemotherapy.